| Domain | Evidence-backed finding | Quantitative data | Ontology/identifier suggestions |
|---|---|---|---|
| Disease definition | Ultra-rare Mendelian disorder of deficient FGF23 activity or signaling, characterized by renal phosphate retention, hyperphosphatemia, inappropriately normal/high calcitriol, and ectopic calcium-phosphate deposition; hyperostosis-hyperphosphatemia syndrome represents an overlapping phenotypic spectrum. (pqac-00000001, pqac-00000007) | Reported manifestations range from biochemical-only disease to massive disabling calcinosis. | Orphanet:306661; OMIM:211900; suggested synonym: hyperphosphatemic familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome (HFTC/HHS). |
| Molecular subtypes | HFTC1 results from biallelic **GALNT3** variants; HFTC2 from biallelic **FGF23** variants; HFTC3 from biallelic **KL** variants. (pqac-00000000, pqac-00000008) | Literature through 2017 identified 44 GALNT3, 19 FGF23, and 1 KL cases among 64 reported cases. | HFTC1—OMIM:211900; HFTC2—OMIM:617993, MONDO:0060714; HFTC3—OMIM:617994, MONDO:0060715. |
| Causal genes and inheritance | **GALNT3** loss impairs protective O-glycosylation of FGF23; **FGF23** loss-of-function impairs hormone secretion/stability; **KL** loss causes resistance to FGF23 signaling. Inheritance is autosomal recessive, usually through germline homozygous or compound-heterozygous variants. (pqac-00000005, pqac-00000007) | GALNT3 is the most frequently reported cause; heterozygous carriers are generally unaffected. | HGNC gene symbols: GALNT3, FGF23, KL; Open Targets disease associations support all three genes. (pqac-00000000) |
| Hallmark biochemistry | Deficient FGF23 action causes excessive proximal-tubular phosphate reabsorption and failure to suppress calcitriol. GALNT3/FGF23 disease generally shows low or inappropriately normal intact FGF23 with markedly elevated C-terminal FGF23 fragments; KL disease shows high intact FGF23 because of hormone resistance. (pqac-00000003, pqac-00000005) | NIH cohort: TRP 96.5%, median TmP/GFR 6.5 mg/dL, median 1,25(OH)₂D 62 pg/mL, and median calcium-phosphate product 63.5 mg²/dL². (pqac-00000013) | HPO suggestion: Hyperphosphatemia—HP:0002905; laboratory concepts: serum phosphate, TmP/GFR, TRP, intact FGF23, C-terminal FGF23, 1,25-dihydroxyvitamin D. |
| Tumoral calcinosis | Lobular calcium-phosphate masses arise chiefly in periarticular skin, subcutaneous tissue, and connective tissue, especially near the hips, elbows, and shoulders; lesions may be painful, inflamed, ulcerating, infected, and functionally disabling. (pqac-00000003, pqac-00000009) | Six of eight NIH-cohort participants had clinically evident tumoral calcinosis; one initially asymptomatic participant subsequently developed elbow calcinosis. (pqac-00000013) | HPO suggestions: Calcinosis; Subcutaneous calcification; Joint limitation; Pain. UBERON suggestions: skin, subcutaneous tissue, hip joint, elbow joint, shoulder joint; exact term identifiers should be ontology-verified. |
| Skeletal and inflammatory disease | Diaphyseal cortical hyperostosis causes episodic painful swelling, warmth, and erythema and may mimic bacterial osteomyelitis or chronic recurrent multifocal osteomyelitis. Calcific lesions can provoke macrophage-rich chronic inflammation and heterotopic ossification. (pqac-00000014, pqac-00000015) | Three of eight NIH subjects had severe systemic inflammation; biopsies from four showed ectopic calcification with chronic inflammation. (pqac-00000014, pqac-00000015) | HPO suggestions: Hyperostosis; Limb pain; Elevated C-reactive protein; Fever; Soft-tissue swelling. GO suggestions: inflammatory response—GO:0006954; biomineral tissue development—GO:0031214. |
| Dental phenotype | Characteristic findings include shortened or thistle-shaped roots, midroot bulges with apical thinning, pulp calcification or obliteration, and pulp stones; premolars are usually most severely affected. (pqac-00000012) | Pulp obliteration occurred in 13/14 evaluable patients (93%); all 10 comprehensively examined patients with GALNT3 variants had shortened thistle-shaped roots and pulp obliteration. (pqac-00000012) | HPO suggestions: Abnormality of dental root; Pulp calcification; Short tooth roots. Exact identifiers require ontology verification. |
| Other anatomy and complications | Reported involvement includes vascular and coronary calcification, colonic submucosal deposits, ocular and testicular calcification, joint or growth-plate destruction, and reduced range of motion. (pqac-00000004, pqac-00000007) | Coronary calcification above the 95th percentile occurred in 2/5 evaluated NIH subjects, although confounding cardiovascular risks prevent attribution solely to HFTC. (pqac-00000014) | UBERON suggestions: coronary artery, colon, eye, testis, growth plate, articular joint; HPO suggestions: Vascular calcification, Joint destruction, Abnormality of the intestine. Exact identifiers should be verified. |
| Diagnostic pattern | Diagnosis rests on persistent age-adjusted hyperphosphatemia, inappropriately high TRP/TmP-GFR, normal renal function, normal serum calcium, and nonsuppressed calcitriol, followed by sequencing and deletion/duplication analysis of GALNT3, FGF23, and KL. Intact-versus-C-terminal FGF23 assays help distinguish hormone deficiency/cleavage from KL-mediated resistance. (pqac-00000005, pqac-00000013) | Normal calcium, creatinine, and alkaline phosphatase accompanied hyperphosphatemia in the NIH cohort. (pqac-00000006) | Suggested genetic-test targets: GALNT3, FGF23, KL. Differential concepts: renal-failure-associated tumoral calcinosis, hyperparathyroidism, calcinosis universalis, dystrophic calcification, chronic osteomyelitis, and autoimmune anti-FGF23 tumoral calcinosis. |
| Medical treatment | Current off-label management combines dietary phosphate restriction, non-calcium phosphate binders such as sevelamer, and phosphaturic agents such as acetazolamide or probenecid. Evidence is limited to case reports and small uncontrolled cohorts, with inconsistent biochemical and lesion responses. (pqac-00000001, pqac-00000006, pqac-00000009) | Suggested dietary phosphate intake in the NIH cohort was 400–900 mg/day; one mass resolved after 13 months of combined treatment. (pqac-00000006, pqac-00000015) | CHEBI suggestions: phosphate—CHEBI:26020; acetazolamide, sevelamer, probenecid, and aluminum hydroxide require identifier verification. NCIT suggestions: Dietary Therapy, Pharmacotherapy, Surgical Excision; exact codes not asserted. |
| Anti-inflammatory and surgical treatment | Anakinra or canakinumab may suppress severe IL-1-mediated inflammation but does not directly correct FGF23 deficiency. Surgery is reserved for painful, infected, ulcerating, or disabling masses because incomplete excision and persistent hyperphosphatemia favor recurrence and wound morbidity. (pqac-00000004, pqac-00000015) | IL-1 blockade reduced CRP in two severely inflamed NIH patients; one had resolution of calcinosis cutis and surrounding inflammation, and both reported improved well-being. (pqac-00000015) | NCIT term suggestions: Anakinra; Canakinumab; Interleukin-1 Inhibition; Surgical Excision—exact codes should be verified. |
| Epidemiology and course | Population prevalence and incidence have not been reliably estimated. Reports suggest enrichment in African and Middle Eastern families, often in association with consanguinity. Onset and expressivity vary markedly, including within families. (pqac-00000002, pqac-00000007) | Onset ranges from infancy or the first decade through late adulthood; a 2023 genetically diagnosed patient developed calcinosis in her seventies. (pqac-00000002, pqac-00000010) | Orphan-disease designation appropriate; no validated sex ratio, carrier frequency, penetrance percentage, survival statistic, or population-screening program is available. |
| Animal models | **Galnt3**-null mice reproduce low circulating intact Fgf23 and hyperphosphatemia despite increased bone Fgf23 expression, but do not consistently develop overt calcific masses. **Fgf23**-null mice reproduce hyperphosphatemia, elevated calcitriol, and ectopic/vascular calcification. (pqac-00000016) | Galnt3-null mice had approximately one-half the circulating intact Fgf23 concentration of controls; the phenotype included sex-specific growth, fertility, and bone-density effects. | Species: *Mus musculus*, NCBI Taxonomy:10090. Model types: Galnt3 knockout and Fgf23 knockout. GO suggestions: phosphate-ion homeostasis—GO:0055062; renal phosphate excretion; hormone-mediated signaling—exact additional identifiers require verification. |


*Table: Concise evidence table covering HFTC classification, genetics, biochemical and clinical phenotypes, diagnosis, management, epidemiology, and experimental models. Quantitative findings are separated from suggested ontology mappings, with uncertain mappings explicitly flagged for verification.*